In Brief: ChromaVision
This article was originally published in The Gray Sheet
Executive Summary
ChromaVision: Automated microscope systems manufacturer inks exclusive three-year distribution and joint development pact with Sigma Aldrich's Sigma Diagnostics division. Under the terms of the deal, Sigma gains worldwide marketing rights to San Juan Capistrano, California-based ChromaVision's prenatal Down syndrome screening test. The test, which is currently in clinical trials in the U.S. and Great Britain, uses Sigma Diagnostics' reagents and the ChromaVision Dx2000 automated intelligent microscope...
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.